Newland Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 490.1 million compared to CNY 448.29 million a year ago. Revenue was CNY 490.1 million compared to CNY 448.29 million a year ago.

Net income was CNY 136.68 million compared to CNY 89.29 million a year ago. Basic earnings per share from continuing operations was CNY 0.6833 compared to CNY 0.8929 a year ago. Diluted earnings per share from continuing operations was CNY 0.6833 compared to CNY 0.8929 a year ago.